Global Patent Index - EP 2021474 A2

EP 2021474 A2 2009-02-11 - RAGE FUSION PROTEINS, FORMULATIONS, AND METHODS OF USE THEREOF

Title (en)

RAGE FUSION PROTEINS, FORMULATIONS, AND METHODS OF USE THEREOF

Title (de)

RAGE-FUSIONSPROTEINE, FORMULIERUNGEN DARAUS UND VERFAHREN ZU IHRER VERWENDUNG

Title (fr)

PROTÉINES DE FUSION RAGE, FORMULATIONS ET LEURS PROCÉDÉS D'UTILISATION

Publication

EP 2021474 A2 (EN)

Application

EP 07794379 A

Priority

  • US 2007010125 W
  • US 79845506 P

Abstract (en)

[origin: WO2007130302A2] Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin C<SUB>H</SUB>2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.

IPC 8 full level (invention and additional information)

C12N 15/13 (2006.01); A61K 38/17 (2006.01); C07K 14/705 (2006.01); C07K 16/00 (2006.01); C12N 15/62 (2006.01)

CPC (invention and additional information)

C07K 14/70503 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)

Citation (search report)

See references of WO 2007130302A3

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

EPO simple patent family

WO 2007130302 A2 20071115; WO 2007130302 A3 20080403; AR 060862 A1 20080716; AU 2007248784 A1 20071115; AU 2007248784 B2 20131121; BR PI0711193 A2 20130618; CA 2651348 A1 20071115; CN 101548012 A 20090930; DO P2007000089 A 20071115; EA 017291 B1 20121130; EA 200870502 A1 20090630; EP 2021474 A2 20090211; EP 2380983 A2 20111026; EP 2380983 A3 20121205; IL 194482 D0 20110801; JP 2009536201 A 20091008; JP 5558810 B2 20140723; KR 20090008459 A 20090121; MX 2008013863 A 20081114; NL 2000626 A1 20071106; NZ 571692 A 20120112; PE 03972008 A1 20080428; SG 171670 A1 20110629; TW 200801036 A 20080101; US 2008045455 A1 20080221; US 2011282035 A1 20111117; US 7981424 B2 20110719; US 8344120 B2 20130101; UY 30324 A1 20080102; ZA 200809394 B 20090729

INPADOC legal status


2016-06-08 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20151203

2015-11-11 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: VTV THERAPEUTICS LLC

2015-08-19 [INTG] ANNOUNCEMENT OF INTENTION TO GRANT

- Effective date: 20150723

2015-08-19 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: VTV THERAPEUTICS LLC

2015-08-12 [RIN1] INVENTOR (CORRECTION)

- Inventor name: ROTHLEIN, ROBERT

2015-08-12 [RIN1] INVENTOR (CORRECTION)

- Inventor name: WEBSTER, JEFFREY C.

2015-08-12 [RIN1] INVENTOR (CORRECTION)

- Inventor name: MJALLI, ADNAN M.M.

2015-08-12 [RIN1] INVENTOR (CORRECTION)

- Inventor name: BENJAMIN, ERIC J.

2015-08-12 [RIN1] INVENTOR (CORRECTION)

- Inventor name: TIAN, YE EDWARD

2014-03-26 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: TRANSTECH PHARMA, LLC

2009-06-24 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20090526

2009-02-11 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20081124

2009-02-11 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A2

- Designated State(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

2009-02-11 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO

- Countries: AL BA HR MK RS